At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to find the best dose of CB-011 to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing even after treatment.
- A Study Using Immune Suppression Prior to Stem Cell Transplant for Children and Adults with Sickle Cell Disease or Beta-Thalassemia
Full Title Pre-Transplant Immune Suppression with Hematopoietic Cell Transplantation from Haploidentical Donors for Adults and Children with Sickle Cell Disease or ß-Thalassemia (Haplo PTCy)
Purpose
Sickle cell disease and beta-thalassemia are blood diseases caused by a genetic change (mutation) in hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with these diseases may be offered a stem cell transplant. Stem cell transplantation involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in the bone marrow.
In this study, researchers want to determine if giving medications to quiet down the immune system before standard conditioning therapy and stem cell transplantation can reduce the risk of serious side effects of transplant. Participants will receive fludarabine and dexamethasone (medications that lower the activity of the immune system) before standard conditioning therapy and stem cell transplantation. Depending on how the body responds to fludarabine and dexamethasone, the study doctor may decide a patient should receive another medication, called cyclophosphamide, instead of fludarabine. In addition, depending on the results of routine blood tests, participants may receive the drugs bortezomib and rituximab, which also help with immune suppression.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have sickle cell disease or beta-thalassemia and be candidates for a donated stem cell transplant.
- Prior stem cell transplantation from a donor is not permitted.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people ages 2-50.
Contact
For more information about this study and to ask about eligibility, please contact 1-833-MSK-KIDS.
Protocol
23-009Phase
Phase II (phase 2)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05736419ClinicalTrials.gov
-
Researchers want to find the best dose of STP938 to treat lymphoma and see how well this drug works against this cancer. The people in this study have B-cell or T-cell lymphoma that keeps growing even with treatment. Examples of these cancers include:
-
Researchers want to see if ruxolitinib works well as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL). T-LGLL is a rare cancer of white blood cells called lymphocytes. The people in this study have T-LGLL that keeps growing even with treatment.
-
Researchers are seeking the best dose of CLSP-1025 to use in people with advanced solid tumors. The people in this study have cancers with a mutation (change) in the p53 gene called R175H. They are also positive for a specific human leukocyte antigen (HLA type A*0201). HLA is a protein on cells that plays an important role in the immune response to foreign substances.
- Improving Cord Blood Transplantation Outcomes for Adults With High-Risk Blood Cancers
Full Title Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Purpose
Umbilical card blood is rich in healthy, blood-forming cells (stem cells) that are very good at fighting blood cancers. Cord blood transplants (CBT) are a standard treatment for adults with blood cancers who lack a genetically matched stem cell donor. Cord blood is donated by a baby’s mother at birth. CBT uses stem cells from cord blood collections to replace cells that have been destroyed by disease or anti-cancer treatment.
Memorial Sloan Kettering Cancer Center (MSK) has developed a standard (“optimized”) practice for CBT using FDA-approved drugs. This optimized practice includes standards for:
- How patients are assessed as candidates for transplant
- The conditioning treatment (standard chemotherapy and total body radiation therapy) used to prepare for transplant
- The amount of stem cells transplanted
- How people are followed during and after CBT
- How patients are monitored for complications after CBT
The purpose of this study is to see if MSK’s optimized CBT practice is safer and more effective. The people in this study have blood cancers with a high risk of returning after treatment, including:
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Other acute leukemias
- Myelodysplastic syndromes
- Myeloproliferative disorders
- Non-Hodgkin lymphoma
- Blastic plasmacytoid dendritic cell neoplasm
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the blood cancers listed above, which has a high chance of coming back after treatment.
- Be recommended for a cord blood transplant.
- Have recovered from the serious side effect of previous therapies.
- Be age 21-65.
Contact
For more information about this study and to see if you can join, please call Dr. Ioannis Politikos’ office at 646-608-3773.
Protocol
23-143Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05884333ClinicalTrials.gov
-
AZD5492 is called a T cell-engaging antibody. AZD5492 helps the immune system target and eliminate cancer cells.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).
-
Urothelial cancers can grow in different parts of the urinary tract. This includes the ureter (the tube that carries urine from the kidneys to the bladder) and renal pelvis. The renal pelvis is where the ureter connects to the kidneys. The standard treatment is surgery to remove the ureter, kidney, or both. In this study, researchers want to see if enfortumab vedotin, given before surgery, is useful for treating urothelial cancers. The people in this study have high-risk urothelial cancers of the upper urinary tract. High risk means there is a greater chance of the cancer coming back after treatment.